Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC).

Rajpurkar, Madhvi; Croteau, Stacy E; Boggio, Lisa; Cooper, David L

Rajpurkar, Madhvi; Croteau, Stacy E; Boggio, Lisa; Cooper, David L.

Afiliação

Rajpurkar M; Carman and Ann Adams Department of Pediatrics, Children's Hospital of Michigan/Wayne State University, Detroit, MI, USA.
Croteau SE; Department of Pediatrics, Boston Children's Hospital/Harvard Medical School, Boston, MA, USA.
Boggio L; Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL, USA.
Cooper DL; Clinical Development and Medical Affairs - Biopharm, Novo Nordisk Inc., Plainsboro, NJ, USA.

J Blood Med ; 10: 335-340, 2019.

Article em En | MEDLINE | ID: mdl-31572039

Palavras-chave

Glanzmann's thrombasthenia; acquired hemophilia; congenital factor VII deficiency; congenital hemophilia with inhibitors; postmarketing surveillance

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article